VR

Veena Rani

Active Director Director DIN 01123761
DIN 01123761 First appointment Aug 1996 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 1996
Shareholding value •••• Premium profile

About Veena Rani

Data last updated:

Veena Rani is a Director at Austin Pharmaceuticals Limited (since 1996). The company operates in Pharma. Austin Pharmaceuticals Limited reported revenue of ₹5.19 Cr (FY 2024).

DIN 01123761
Primary Designation Director
Industry Pharma
First Appointment 07 Aug 1996
Oldest Company Age 30 yrs
Largest company Austin Pharmaceuticals Limited · ₹5.19 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Austin Pharmaceuticals Limited U51397CH1996PLC018606
Director07 Aug 19961996₹5.19 Cr (FY 2024)Active

Board colleagues of Veena Rani

Directorship timeline

Open interactive timeline →
Austin Pharmaceuticals Limited
Premium access

Shareholding and investment profile for Veena Rani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Veena Rani

Veena Rani currently holds 1 directorship: Austin Pharmaceuticals Limited (Director, since 07 Aug 1996, revenue ₹5.19 Cr (FY 2024)).

Veena Rani was first appointed on 07 Aug 1996 as Director at Austin Pharmaceuticals Limited.

The current boards of Veena Rani's companies include Nischay Singla (Austin Pharmaceuticals Limited), Rakesh Kumar (Austin Pharmaceuticals Limited), Vinayak Singla (Austin Pharmaceuticals Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available